Ripretinib
Qinlock · KIT switch-control inhibitor
Hypertension and alopecia in GIST.
Lupron · Leup
GnRH agonist · approved 1985 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
GnRH agonist whose kidney risk is indirect — metabolic syndrome, bone loss and cardiovascular strain.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No characteristic direct nephrotoxicity. Androgen-deprivation therapy is associated with metabolic syndrome, insulin resistance, dyslipidemia and increased cardiovascular disease, which raise long-term renovascular risk; a systematic review/meta-analysis confirms excess cardiovascular events with androgen-pathway therapy, and preclinical models show GnRH-agonist-induced metabolic syndrome and atherosclerosis. Reported rate: hypertension in 14.6% — 137 subjects with advanced prostate cancer indicated for androgen ablation, receiving leuprolide mesylate subcutaneous… (Shore 2020, PMID 30941562).Source: Shore et al., World J Urol 2020
Metabolic/cardiovascular and skeletal effects emerge over months to years.
Distilled from: “Months to years (metabolic/cardiovascular and skeletal).”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
GnRH (LHRH) agonist that after an initial gonadotropin surge downregulates and desensitizes pituitary GnRH receptors, suppressing LH/FSH and gonadal sex-steroid production (medical castration). Used for prostate cancer and other hormone-responsive conditions.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the GnRH agonist class.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
5 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 79,718 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
12,429 of 79,718 reports
Reported with hospitalization
12,420 of 79,718 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 11,617 of the 79,718 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Leuprolide sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Qinlock · KIT switch-control inhibitor
Hypertension and alopecia in GIST.
Aliqopa · Pan-PI3K inhibitor
Transient infusion-related hypertension and hyperglycemia.
Xtandi · Androgen-receptor inhibitor
Hypertension; rare electrolyte effects.
Scemblix · BCR-ABL STAMP inhibitor
Hypertension and pancreatitis; allosteric BCR-ABL inhibitor.
Calquence · BTK inhibitor
Tumor lysis; lower hypertension than ibrutinib.
Zejula · PARP inhibitor
Hypertension and creatinine rise.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.